Login
$ZBIO
$27.24 +$0.37 (1.38%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Restricted cash
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets, net
Restricted cash
Long-term investments
Other non-current assets
Total assets
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued expenses
Operating lease liabilities, current
Total current liabilities
Long-term liabilities:
Royalty obligation
Senior secured term loan, net
Convertible senior notes, net
Operating lease liabilities, less current portion
Total long-term liabilities
Total liabilities
Stockholders' equity:
Common stock, par value $0.0001 per share; 175,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 63,330,747 and 54,485,518 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support